Abbisko Cayman's (HKG:2256) unit Abbisko Therapeutics said its solid tumor medication ABSK131 received approval for its IND application from the US FDA, according to a Tuesday filing with the Hong Kong bourse.
ABSK131 is a novel small molecule MTA-cooperative PRMT5 inhibitor with strong anti-tumor activity, the filing added.